The stock of Procept BioRobotics Corp (PRCT) has gone down by -4.47% for the week, with a -16.74% drop in the past month and a 2.39% rise in the past quarter. The volatility ratio for the week is 3.96%, and the volatility levels for the past 30 days are 4.17% for PRCT. The simple moving average for the past 20 days is -8.53% for PRCT’s stock, with a 14.15% simple moving average for the past 200 days.
Is It Worth Investing in Procept BioRobotics Corp (NASDAQ: PRCT) Right Now?
Company’s 36-month beta value is 1.02.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PRCT is 48.95M, and currently, short sellers hold a 11.27% ratio of that floaft. The average trading volume of PRCT on October 18, 2024 was 697.20K shares.
PRCT) stock’s latest price update
The stock of Procept BioRobotics Corp (NASDAQ: PRCT) has decreased by -4.66 when compared to last closing price of 72.46.Despite this, the company has seen a loss of -4.47% in its stock price over the last five trading days. globenewswire.com reported 2024-10-09 that SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.
Analysts’ Opinion of PRCT
Many brokerage firms have already submitted their reports for PRCT stocks, with Piper Sandler repeating the rating for PRCT by listing it as a “Overweight.” The predicted price for PRCT in the upcoming period, according to Piper Sandler is $42 based on the research report published on August 11, 2023 of the previous year 2023.
PRCT Trading at -7.87% from the 50-Day Moving Average
After a stumble in the market that brought PRCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.50% of loss for the given period.
Volatility was left at 4.17%, however, over the last 30 days, the volatility rate increased by 3.96%, as shares sank -16.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.00% upper at present.
During the last 5 trading sessions, PRCT fell by -4.47%, which changed the moving average for the period of 200-days by +66.70% in comparison to the 20-day moving average, which settled at $75.52. In addition, Procept BioRobotics Corp saw 64.83% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRCT starting from Waters Kevin, who sale 25,000 shares at the price of $72.47 back on Oct 15 ’24. After this action, Waters Kevin now owns 96,096 shares of Procept BioRobotics Corp, valued at $1,811,653 using the latest closing price.
Waters Kevin, the EVP, CFO of Procept BioRobotics Corp, sale 25,000 shares at $82.51 during a trade that took place back on Sep 16 ’24, which means that Waters Kevin is holding 96,096 shares at $2,062,679 based on the most recent closing price.
Stock Fundamentals for PRCT
Current profitability levels for the company are sitting at:
- -0.62 for the present operating margin
- 0.53 for the gross margin
The net margin for Procept BioRobotics Corp stands at -0.59. The total capital return value is set at -0.33. Equity return is now at value -50.88, with -32.07 for asset returns.
Based on Procept BioRobotics Corp (PRCT), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -1.73. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -50.27.
Currently, EBITDA for the company is -105.36 million with net debt to EBITDA at 1.26. When we switch over and look at the enterprise to sales, we see a ratio of 19.56. The receivables turnover for the company is 3.0for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.51.
Conclusion
In a nutshell, Procept BioRobotics Corp (PRCT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
